Atrial natriuretic peptide and long-acting natriuretic peptide inhibit Ras in human prostate cancer cells

Anticancer Research

Volumn 29, Issue 6, 2009, Pages 1889-1893

  Sun, Ying ^a   Eichelbaum, Ehrentraud J ^a   Lenz, Anne ^a   Skelton IV, William P ^a   Wang, Hai ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Atrial natriuretic peptide; Cardiac hormones; Long acting atrial natriuretic peptide; Prostate cancer; Ras

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CYCLIC GMP; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; RAS PROTEIN; UNCLASSIFIED DRUG;

AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA;

ADENOCARCINOMA; AGED; ATRIAL NATRIURETIC FACTOR; BLOTTING, WESTERN; CYCLIC GMP; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RAS PROTEINS;

EID: 67650925065     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Scholl FA, Dumesic PA and Khavari PA: Effects of active MEK 1 expression in vivo. Cancer Lett 230: 1-5, 2005.
2. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangeliste C, Martelli AM and Franklin RA: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
3. Sebolt-Leopold JS: Advances in the development of cancer therapeutics directed against the Ras mitogen-activated protein kinase pathway. Clin Can Res 14: 3651-3656, 2008.
4. McCubrey JA, Milella M, Tafuri A, Martelli AM, Lunghi P, Bonati A, Cervello M, Lee JT and Steelman LS: Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 9: 614-630, 2008. (Pubitemid 351777165)
5. Sebolt-Leopold JS and Herrera R: Targeting the mitogen-activated protein kinase cascade to treat cancer. Nature Rev Cancer 4: 937-947, 2004. (Pubitemid 39626217)
6. Roberts PJ, and Der CJ: Targeting the RAF-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291-3310, 2007. (Pubitemid 46763022)
7. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL and Gower WR Jr: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21: 445-452, 2007. (Pubitemid 46901402)
8. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA and Gower WR Jr: Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 21: 973-978, 2007. (Pubitemid 350286323)
9. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27: 3813-3818, 2007.
10. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 26: 4143-4148, 2006. (Pubitemid 46031483)
11. Waldman SA, Rapoport RM and Murad F: Atrial natriuretic factor selectively activates membranous guanylate cyclase and elevates cyclic GMP in rat tissues. J Biol Chem 259: 14332-14334, 1984. (Pubitemid 15222241)
12. Vesely DL: Signal transduction: Activation of guanylate cyclase-cyclic guanosine-3′-5′ monophosphate system by hormones and free radicals. Am J Med Sci 314: 311-323, 1997. (Pubitemid 27481528)
13. Stone KR, Mickey DD, Wunderli H, Mickey GH and Paulson DF: Isolation of a human prostate carcinoma cell line (DU-145). Int J Cancer 21: 274-281, 1978. (Pubitemid 8283045)
14. deRooij J and Bos JL: Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe of Ras. Oncogene 14: 623-625, 1997.
15. Bos JL: Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-4689, 1989. (Pubitemid 19213607)
16. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Insulin and epidermal growth factor activation of ERK 1/2 and DNA synthesis is inhibited by four cardiac hormones. J Cancer Mol 3(4): 113-120, 2007.
17. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Cardiac hormones activate ERK 1/2 kinases in human fibroblasts. Horm Metab Res 41: 197-201, 2009.
18. Vesely BA, Alli AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005. (Pubitemid 41640906)